SureTrader
Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Drugs >

Innovation Pharmaceuticals Inc. (IPIX)

IPIX RSS Feed
Add IPIX Price Alert      Hide Sticky   Hide Intro
Moderator: LilKahuna, BooDog, sox040713, Astavakra, Matagordaville, scottsmith
Search This Board: 
Last Post: 11/23/2017 11:46:50 AM - Followers: 727 - Board type: Free - Posts Today: 27

Innovation Pharmaceuticals Inc. (IPIX)

https://www.sec.gov/Archives/edgar/data/1355250/000147793217002710/ctix_8k.htm
 

http://www.ipharminc.com/

 
Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-236-8717
Fax:  978-921-6564
Email:  info@ipharminc.com

 
About Innovation Pharmaceuticals Inc.: 

Headquartered in Beverly, Massachusetts, Innovation Pharmaceuticals is a publicly-traded company under the symbol "IPIX".
Innovation Pharmaceuticals is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Innovation Pharmaceuticals believes it has a world-class portfolio of first-in-class lead drug candidates and is now advancing them toward market approval, while actively seeking strategic partnerships. Innovation Pharmaceuticals' psoriasis drug candidate Prurisol completed a Phase 2 trial and Innovation Pharmaceuticals is nearing completion of a Phase 2b study. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Innovation Pharmaceuticals' anti-cancer drug Kevetrin successfully concluded a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Innovation Pharmaceuticals has commenced a Phase 2 study. In the laboratory, Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Innovation Pharmaceuticals is in a Phase 2 clinical trial with its novel compound Brilacidin-OM (a defensin mimetic compound) for the prevention of oral mucositis in patients with head and neck cancer. Interim analysis has shown Brilacidin-OM to have a high potential for prevention of severe oral mucositis. Clinical results are consistent with those seen in an animal model in which the occurrence of severe ulcerative oral mucositis was reduced by more than 94% compared to placebo. Innovation Pharmaceuticals' lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infection, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria ("superbugs"). In an ongoing Phase 2 open label Proof-of-Concept trial, favorable interim results have been observed in the first two cohorts of patients treated with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Disease (IBD).  Innovation Pharmaceuticals has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available at http://www.ipharminc.com.

Management: http://www.cellceutix.com/senior-management/

Ongoing Human Trials:  http://clinicaltrials.gov/ct2/results?term=Cellceutix+Pharmaceuticals&Search=Search
 
Product Pipeline:  http://www.ipharminc.com/therapeutic-areas/

 

PIPELINE: 

FDA DESIGNATIONS:

MILESTONES:


Recent News and Press Releases: 
https://finance.yahoo.com/quote/IPIX?p=IPIX
http://www.ipharminc.com/press-release/

 
SEC Filings (CIK:0001355250): 
https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany

Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com

 
Share Structure:  See SEC filing link above for current share structure

 

Cellceutix IP - Patent Filings:

EPO
http://worldwide.espacenet.com/searchResults?PA=Cellceutix&DB=EPODOC&locale=en_EP&ST=advanced&compact=false
WIPO
http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO2010135170&recNum=1&docAn=US2010034838&queryString=FP:(Cellceutix)&maxRec=1
USPTO
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=Cellceutix&FIELD1=AS&co1=AND&TERM2=&FIELD2=&d=PG01 


http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,796,275.PN.&OS=PN/8,796,275&RS=PN/8,796,275
 

Publication number US8338454 B2
Publication type Grant
Application number US 12/780,132
Publication date Dec 25, 2012
Filing date May 14, 2010
Priority date May 20, 2009
Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »
Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2
Inventors Krishna Menon
Original Assignee Cellceutix Corporation
Export Citation BiBTeX, EndNote, RefMan
Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42)
 
External Links: USPTO, USPTO Assignment, Espacenet

http://www.google.com/patents/US8338454

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=6&f=G&l=50&co1=AND&d=PG01&s1=Cellceutix.AS.&OS=AN/Cellceutix&RS=AN/Cellceutix

 
Investor Relations: 

http://www.ipharminc.com/new-faq/
http://www.ipharminc.com/contact-us-1


Following is a DAILY chart:


 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

SureTrader
Interactive Brokers Advertisement
IPIX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IPIX News: Prospectus Filed Pursuant to Rule 424(b)(2) (424b2) 11/13/2017 10:03:05 AM
IPIX News: Quarterly Report (10-q) 11/08/2017 04:04:57 PM
IPIX News: Notice of Effectiveness (effect) 09/22/2017 06:02:17 AM
IPIX News: Securities Registration Statement (simplified Form) (s-3) 09/11/2017 12:47:10 PM
IPIX News: Annual Report (10-k) 09/11/2017 06:04:38 AM
PostSubject
#203170  Sticky Note Doesn't seem at all reasonable that any person DaysOnTheBeach 11/09/17 10:51:58 AM
#202469  Sticky Note B-OM Due Diligence sox040713 11/03/17 04:42:35 PM
#200759  Sticky Note IPIX is looking for partnerships after P2's. petemantx 10/19/17 10:14:05 PM
#200267  Sticky Note Cellceutix Reports Very Encouraging Interim Analysis of Phase scottsmith 10/16/17 07:19:09 PM
#200091  Sticky Note IPIX Clinical Trial Timelines sox040713 10/14/17 08:13:18 PM
#197995  Sticky Note IPIX Milestones, Clinical Trials, Recent Interviews, Corporate Overview, Patents sox040713 09/24/17 05:24:48 PM
#187085  Sticky Note When it is easier to find an off IH Admin [Edward] 06/23/17 04:39:38 PM
#204714   It's not Thanksgiving where he's at... runninggirl2016 11/23/17 11:46:50 AM
#204713   Amen Blues44 11/23/17 11:40:17 AM
#204712   It’s Thanksgiving. Can’t you give it a rest LilKahuna 11/23/17 11:39:31 AM
#204711   Of course the grinch comes in groton68 11/23/17 11:37:43 AM
#204710   it will be just another week of delays, MXAMDUD 11/23/17 11:29:28 AM
#204709   We told em that for the last 3 scottsmith 11/23/17 11:26:15 AM
#204708   Let’s all pass on a suggestion to friends Cassius Longinus 11/23/17 11:04:41 AM
#204707   OM trial history is a bit more complicated. PlentyParanoid 11/23/17 10:51:52 AM
#204706   So will next week be the week of snayeman 11/23/17 10:47:17 AM
#204705   Sounds Splendid to me : ) have WILD_4_IPIX 11/23/17 10:05:23 AM
#204704   LilKahuna That post should sell B, K and P Echo20 11/23/17 09:56:02 AM
#204703   Wild4IPIX Thanks I will have a conservative dinner. Echo20 11/23/17 09:51:27 AM
#204702   That's a very compelling POST and I'm personally WILD_4_IPIX 11/23/17 09:38:17 AM
#204701   I agree with georgejjl. CallMeCrazy 11/23/17 09:32:28 AM
#204700   Thanks E20 ! Don't eat as much as WILD_4_IPIX 11/23/17 09:31:16 AM
#204699   CallMeCrazy 11/23/17 09:30:25 AM
#204698   LilKahuna That was possibly the best post you ever made!!! georgejjl 11/23/17 09:03:22 AM
#204697  Restored Happy Thanksgiving!!! georgejjl 11/23/17 08:57:05 AM
#204696   Awesome! Happy thanksgiving to you and all the Jhawker 11/23/17 08:34:13 AM
#204695   nice read this morning here in the very To infinity and beyond! 11/23/17 08:11:43 AM
#204694   Very nic JUST 10-11-12 11/23/17 07:33:27 AM
#204693   I love Thanksgiving,.. we already had ours up cabel 11/23/17 07:32:10 AM
#204692   Eloquent!!! Happy Thanksgiving BK. God bless all F1ash 11/23/17 07:04:12 AM
#204691   Great Post! I needed that... Well said and LilyGDog 11/23/17 06:11:31 AM
#204690   Thanksgiving thoughts from across the grand ocean: LilKahuna 11/23/17 04:15:08 AM
#204689   So what you are claiming is that a septmike09 11/23/17 12:12:34 AM
#204686   IPIX likely heading to the big leagues and Williamsc 11/22/17 10:07:51 PM
#204685   Exactly, I wouldn't invest in a stock if sox040713 11/22/17 09:31:02 PM
#204684   Yes, they hold a very small portion of frrol 11/22/17 09:11:50 PM
#204683   Boom! Well stated. IPIX Detonate 11/22/17 08:07:51 PM
#204681   Something I don't understand,... all the other F1ash 11/22/17 07:46:34 PM
#204679   New investors, FINRA didn't say "40% of today's sox040713 11/22/17 07:38:33 PM
#204678   Look at the bright side, at least the sox040713 11/22/17 07:34:04 PM
#204677   Definitely gets my vote for "Greatest Rebuttals "!hub.... alwaysdreaming 11/22/17 07:16:52 PM
#204675   Old memories coming back - 2015 SF - Amatuer17 11/22/17 05:41:17 PM
#204674   FINRA short sales of IPIX AlanC 11/22/17 05:38:32 PM
#204673   Well that is twisting the fact Leo applied for Amatuer17 11/22/17 05:37:51 PM
#204672   Correct, adding more supply to an investment that Rdunn88 11/22/17 05:00:40 PM
#204671   The company doesn't have surplus cash to do KarinCA 11/22/17 04:59:16 PM
#204670   They have sold the rest in the open market. groton68 11/22/17 04:43:13 PM
#204668   Another item that slows patient enrollment can be KarinCA 11/22/17 04:26:55 PM
#204667   Under 5 percent is 6 million shares, so Rdunn88 11/22/17 04:23:52 PM
#204666   Each sale likely hasn’t generated a profit. scottsmith 11/22/17 04:14:49 PM
#204665   They stay just under 5%. groton68 11/22/17 04:01:47 PM
#204664   Correct, Aspire's business is dependent on companies like Rdunn88 11/22/17 04:01:02 PM
#204663   It’s hilarious. The filings are clear. scottsmith 11/22/17 03:52:27 PM
#204662   Brilacidin ph2 Oral Mucositis trial actually completed earlier KarinCA 11/22/17 03:51:59 PM
#204661   Aspire are not long-term holders of IPIX. If Rdunn88 11/22/17 03:50:50 PM
#204660   You are absolutely wrong. They hold. Read their literature groton68 11/22/17 03:45:43 PM
#204658   CDA’s and money coming in are two different things groton68 11/22/17 03:44:45 PM
PostSubject